Revolution Medicines, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Revolution Medicines, Inc. | RVMD - NASDAQ |
$16.00-$17.00 | $17.00 | $28.21 | 14 million | 2/13/2020 |
| JP Morgan, Cowen, SVB Leerink, Guggenheim | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-01-18 Terms Added 2020-02-03 Terms Changed 2020-02-11 | ||||||
Revolution Medicines, Inc. Quote & Chart - Click for current quote - RVMD
IPO Boutique aggregates information on public companies and private companies, such as "RVMD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Revolution Medicines, Inc. (adapted from Revolution Medicines, Inc. prospectus):
They are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "RVMD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.